SCHEMBL738600

SCHEMBL738600

O=C(c1ccc2[nH]cnc2c1)N1CCC2(CCc3ccccc32)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.53
KDM4E B2RXH2 2/20 0.53
HSD11B1 P28845 8/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RBP4 P02753 1/20 0.43
CRBN Q96SW2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 1/20 0.42
ACACB O00763 1/20 0.41
SLC18A3 Q16572 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12576940 0.92 KDM4E (0.64) HPGDSKDM4EHSD11B1MEN1KMT2A
SCHEMBL762611 0.81 MAPK14 (0.54) HPGDSHSD11B1L3MBTL1RBP4MAPT
SCHEMBL738652 0.78 MCHR2 (0.54) KDM4EHSD11B1MEN1KMT2AL3MBTL1
SCHEMBL1063453 0.78 L3MBTL1 (0.57) KDM4EMEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL5455303 0.78 KDM4E (0.83) KDM4EHSD11B1SMN1; SMN2ALDH1A1LMNA
SCHEMBL740988 0.78 HPGDS (0.58) HPGDS
SCHEMBL740898 0.78 SMN1; SMN2 (0.48) KDM4EMEN1KMT2AL3MBTL1CRBN
SCHEMBL13373550 0.77 HPGD (0.58) KDM4EHSD11B1MEN1KMT2AL3MBTL1
SCHEMBL3841546 0.77 TACR1 (0.55) HPGDSHSD11B1KMT2ARBP4ALDH1A1
SCHEMBL22999769 0.76 KDM4E (0.55) KDM4EHSD11B1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 EP claimed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 WO claimed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 HPGDS 124/4885KDM4E 4521/4885HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.